TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2024-03-26
謝思民Hsieh, Szu-Min
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
-
doceason1967@gmail.com
發表文獻
39筆
21
Wu PY, Sun HY, Chen MY, Sheng WH, Hsieh SM, Chuang YC, Chang HY, Luo YZ, Zhang JY, Hung CC. Participation in cancer screening among people living with HIV at a university hospital. J Microbiol Immunol Infect. 2021 Apr 28:S1684-1182(21)00094-3. doi: 10.1016/j.jmii.2021.04.004. Epub ahead of print. PMID: 33965343.
22
Yeong EK, Sheng WH, Hsueh PR, Hsieh SM, Huang HF, Ko AT, Tai HC, Lai HS, Chang SC. The Wound Microbiology and the Outcomes of the Systemic Antibiotic Prophylaxis in a Mass Burn Casualty Incident. J Burn Care Res. 2020 Jan 30;41(1):95-103. doi: 10.1093/jbcr/irz077. PMID: 31999335.
23
Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC, Lee YL, Lin YL, Shih SR, Huang CG, Liao CC, Liang JJ, Chang CS, Chen C, Lien CE, Tai IC, Lin TY. Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial. Lancet Respir Med 2021; 9: 1396-1406 (01 Dec; online 13 Oct 2021) https://doi.org/10.1016/S2213-2600(21)00402-1
24
Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Durability and immunogenicity of neutralizing antibodies response against Omicron variants after three doses of subunit SARS-CoV-2 vaccine MVC-COV1901: An extension to an open-label, dose-escalation phase 1 study. Infect Dis Ther 2022; 11, 1493–1504 (Online publication: 2022 May 17 https://doi.org/10.1007/s40121-022-00652-6)
25
Waits A, Chen JY, Cheng WH, Yeh JI, Hsieh SM, Chen C, Janssen R, Lien CE, Lin TY. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial. International Journal of Infectious Diseases 2022; 124: 21-26.
26
Chen JY, Hsieh SM, Hwang SJ, Liu CS, Li X, Fournier M, Yeh TY, Yin JK, Samson SI. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study. Vaccine 2022; 40: 6450-6454. https://doi.org/10.1016/j.vaccine.2022.09.078
27
Cheng SH, Lien CE, Hsieh SM, et al. A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV. Vaccines 2023; 11(1) https://doi.org/10.3390/vaccines11010018
28
Chen GJ, Sun HY, Lin KY, Hsieh SM, Chuang YC, Liu WD, Huang YS, Pan SC, Wu UI, Cheng A, Huang YC, Wu CH, Su YC, Liu WC, Chang SY, Huang CC. A randomized clinical trial of one-dose versus accelerated two-dose schedule for hepatitis A virus revaccination among people with HIV who were non-responders or had seroreversion after primary HAV vaccination. Clin Infect Dis 2023 (April 10) https://doi.org/10.1093/cid/ciad206
29
Lila Estephan, Ying-Chin Lin, Yi-Tsung Lin, Yen-Hsu Chen, Sung-Ching Pan, Szu-Min Hsieh, Paal Fure Torkehagen, Yi-Jen Weng, Hao-Yuan Cheng, Josue Antonio Estrada, Alexander Waits, Charles Chen, Chia En Lien. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. Vaccine 2023 (April 12) https://doi.org/10.1016/j.vaccine.2023.04.029
30
Huang ST, Huang YS, Liu WD, Pan SC, Sun HY, Lien CE, Chen C, Hsieh SM*. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study. J Formos Med Assoc 2023; 122: 1165-1173. https://doi.org/10.1016/j.jfma.2023.05.030 (*Correspondence author)
